The Cali Fund is the global fund associated with the multilateral mechanism established under the Convention on Biological Diversity (CBD) to share benefits arising from the use of digital sequence information (DSI) on genetic resources. It is intended to channel contributions from commercial users of such information into the conservation and sustainable use of biodiversity, including support for Indigenous peoples and local communities. Named after Cali, Colombia, where its operating arrangements were agreed in 2024, the fund was launched in Rome on 25 February 2025.
Background and purpose
Genetic sequence information can be stored electronically, shared through databases, and used without obtaining a new physical sample of the organism from which it originated. For example, a researcher may use a published DNA sequence to investigate an enzyme, develop a biotechnology process, or compare genetic characteristics across organisms.
This creates a benefit-sharing challenge. Traditional access and benefit-sharing arrangements often involve permission to obtain genetic material and mutually agreed terms for its use. The Nagoya Protocol provides an international framework for such arrangements. Digital information, however, can move through many databases, research projects, and commercial applications, making benefits difficult to attribute to a particular physical sample or country of origin.
The Cali Fund addresses this problem through a multilateral approach. Rather than requiring each payment to be traced to an individual sequence, it seeks contributions from commercial activities benefiting from DSI and pools those contributions for biodiversity-related purposes.
“Digital sequence information” remains a policy term without a universally agreed definition across all international processes. Genetic sequence data are central to the discussions, but questions about the term’s precise boundaries are distinct from the fund’s financial arrangements.
Establishment
At the CBD’s fifteenth Conference of the Parties in 2022, governments agreed to establish a multilateral mechanism for sharing benefits from the use of DSI, including a global fund. This formed part of the wider negotiations surrounding the Kunming–Montreal Global Biodiversity Framework, whose Target 13 addresses benefit-sharing from genetic resources, DSI, and associated traditional knowledge.
At the sixteenth Conference of the Parties in Cali in November 2024, the parties adopted Decision 16/2, setting out the mechanism’s operating arrangements and naming its financial component the Cali Fund. The launch took place during the resumed session of that conference in Rome in February 2025.
The fund is supported through the United Nations system, with roles for the United Nations Development Programme, the United Nations Environment Programme, and the CBD Secretariat. The United Nations Multi-Partner Trust Fund Office serves as its administrative agent.
Contributions and commercial users
The mechanism identifies sectors that may benefit directly or indirectly from DSI, including:
- Pharmaceuticals.
- Nutraceuticals.
- Cosmetics.
- Animal and plant breeding.
- Biotechnology.
- Laboratory equipment associated with sequencing and the use of DSI.
- Information, scientific, and technical services related to DSI, including artificial intelligence.
The contribution arrangements focus on larger entities rather than on every researcher or organization accessing sequence data.
Under the indicative approach adopted in 2024, entities in relevant sectors that exceed at least two of three financial thresholds, averaged over the preceding three years, should contribute. The thresholds are:
| Financial measure | Threshold |
|---|---|
| Total assets | US$20 million |
| Sales | US$50 million |
| Profit | US$5 million |
The decision specifies indicative contribution rates of 1 per cent of profit or 0.1 per cent of revenue. These are alternative bases, not amounts to be added together.
These provisions do not themselves create a universally enforceable international tax. The CBD decision invites governments to take administrative, policy, or legislative measures to encourage contributions, while implementation depends on the measures adopted in relevant jurisdictions and participation by commercial users. The framework distinguishes commercial benefit-sharing from public research and open scientific access; it does not establish a charge for each sequence downloaded.
Allocation and beneficiaries
The fund’s central purposes are biodiversity conservation and the sustainable use of its components. Its design links the economic benefits generated by biological information with financial support for maintaining the living systems from which that information ultimately derives.
A major allocation provision is that at least half of the fund’s funding should support the self-identified needs of Indigenous peoples and local communities, including women and youth within those communities. The arrangements envisage support through governments or, where appropriate, direct payments through institutions identified by Indigenous peoples and local communities.
This provision reflects the importance of community stewardship and traditional knowledge in biodiversity conservation. It does not mean that every payment is compensation for a specific sequence, species, or traditional practice. Allocation takes place through a pooled international mechanism rather than solely through transactions between individual data users and identifiable providers.
Relationship to other biodiversity mechanisms
The Cali Fund is distinct from the Global Environment Facility and its Global Biodiversity Framework Fund. Those mechanisms support biodiversity financing more broadly; the Cali Fund specifically concerns benefit-sharing from the use of DSI.
It also does not replace all bilateral access and benefit-sharing arrangements or eliminate obligations associated with obtaining physical genetic resources. The distinction between access to genetic material and subsequent use of digital information remains important.
The mechanism combines monetary benefit-sharing with a wider emphasis on non-monetary benefits, such as scientific cooperation, capacity-building, technology transfer, and improved access to research tools. These activities are related to, but not identical with, contributions paid into the fund.
Implementation questions
The fund’s operation depends on determining which businesses benefit from DSI, how relevant financial information is assessed, and how contributions can be mobilized consistently across jurisdictions. Companies may use sequence information indirectly through suppliers, research partners, or analytical services, complicating the identification of relevant commercial activity.
Allocation also requires procedures for accountability, access to funding, and the participation of intended beneficiaries. A further design challenge is to mobilize meaningful financial contributions while preserving open access to scientific data and avoiding unnecessary barriers to research. The multilateral approach was developed partly to address these practical difficulties without requiring the origin and commercial value of every individual sequence to be traced.